Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Dec 01, 2021 10:29am
144 Views
Post# 34184729

RE:RE:RE:RE:RE:New positions

RE:RE:RE:RE:RE:New positionsThe Chief of Staff position is the most interesting of the 9 new positions listed since mid-November. None are totally cancer related as best as I can tell. So, what does that tell us, if anything? Sales of the legacy drugs are improving some but not enough to justify all those hirings. And we do not know what is going on in terms of employees who left and therefore perhaps some of these are just replacements and not new staff. I suspect the Internal Communications Manager is a replacement for Boucher for example and they have simply reimagined that position. 

It is noteworthy that the Chief of Staff has responsibilities of communicating with analysts. Will THTX forego hiring a normal IR person to replace Leah - has that position been re-imagined too? There is no posting for an IR person - do all positions need to be posted or could there be a separate hiring process for some. 

Does the lack of cancer related hirings indicate they expect to be farming out research to big pharma partners? Anyone concerned by the inability to fill the Drug Discovery Scientist position that has been there since April?  

THTX is clearly no longer acting like a company that was suffering from PTSD following a close scare from a potential bankruptcy. They are looking to build the infrastructure to grow and add onto. Let's hope they are not outrunning their headlights though. 

Wino115 wrote: I'd agree with this assessment. That CoS is really only seen in fairly large companies, so it's definitely a Pfizer influenced idea.  But if a company becomes more complex, there's a lot of the day-to-day stuff that needs to be executed and often the guy at the top gets called on to make every silly little decision. Just the requests clog up the inbox.  So to offload the day-to-day and function-oriented decision's to allow the CEO to spend a lot more time on strategy, board, key developments and the big value-driving factors beyond just the execution can be helpful.  Not that I've been a CEO, but anyone who's managed more than 20 people knows there's a tax on your time to answer loads of less important issues. 

Given we all know how conservative and budget oriented the Board is, I have to believe that they wouldn't be doing this kind of bulking up without having a very high degree of confidence in the direction they are moving. They just wouldn't take on all those long-term expenses without knowing it won't crush their cash balance.  It's also on the expensive side to layoff in Canada, so you don't hire without believing they are long term hires.  We saw what happend when they canned the PR guy -- lots of severence and a lawsuit for more. 


realitycheck4u wrote: I am going out on a limb here and saying that there is a very big role with Chief of Staff with tthe way  that role is worded. Does that mean our CEO is about to be way too busy with mundane tasks that are not about the tough job of negotiating, partnering and Selling the big picture to analysts and investors.  This new job is essentially the CEO's job of a company that is not drinking from the firehose.  So, I think if we're about to hire a chief of staff, then we may see some incredible things break out soon. 

palinc2000 wrote:

I am a bit surprised to see a Chief Of Staff amongst the new positions.The job description appears to include a lot of tasks usually performed by the CEO.... I have never seen that in such a small and even much bigger companies...
 

There has to be another shoe to drop....

 

archeo753 wrote: It seems like Paul has very grand plans for the future.  He definitely is building Thera into a much more substantial company than it was before he took the reigns.  Hopefully, it is based on confidence in the future of the pipeline but regardless, whatever happens with the cancer trials, Theratechnologies is a much stronger company than it was a year ago.
 

 

Bucknelly21 wrote: Thera posted 4 new positions today, if I were reading between the lines I would think that things are going well, just a thought 

 

 

 




<< Previous
Bullboard Posts
Next >>